High-Risk HPV and Oral Cancer: What Dental Teams Need to Know

For most of the last thirty years, “high-risk HPV” was a phrase that belonged to gynecology. That is no longer where the burden sits. In the United States, the oropharynx has overtaken the cervix as the most common site of HPV-associated cancer, and the patients presenting with it are sitting in dental chairs years before they reach an oncologist.

This is a practical guide to what high-risk HPV means for a dental practice: which types matter, who is actually at risk, what the disease looks like when it presents, and where the honest limits of chairside screening are.

What “high-risk” actually means

There are more than 100 HPV types, and roughly 40 of them spread through direct sexual contact to genital, oral and pharyngeal tissue. Only a small subset is oncogenic. Those are the high-risk types, and they are distinguished by their ability to persist rather than clear, and to drive malignant transformation through the E6 and E7 oncoproteins.

Within that subset, one type dominates the head and neck. In CDC tissue-registry analysis of oropharyngeal squamous cell carcinoma, HPV-16 accounted for roughly 60 percent of cases, with HPV-18 and the remaining 9-valent high-risk types making up a much smaller share. For a dental audience the practical translation is simple: when clinicians discuss HPV-driven oropharyngeal cancer, they are largely discussing HPV-16.

Most exposure resolves without consequence. The CDC notes that most people clear HPV within one to two years. Malignancy is the uncommon outcome of persistent infection, and it typically takes years to develop after the initial exposure. That latency is precisely why this is a dental problem: the interval between infection and presentation is spent in routine recall appointments.

Why the oropharynx became the primary site

The epidemiological shift is well documented and it is not subtle. CDC surveillance covering 1999 through 2015 found cervical carcinoma rates falling about 1.6 percent per year while oropharyngeal squamous cell carcinoma rates rose among both men and women. By 2015, oropharyngeal SCC had passed cervical carcinoma outright, 18,917 cases to 11,788.

The CDC estimates that HPV causes 60 to 70 percent of oropharyngeal cancers in the United States. Longer-run tissue analysis shows how fast this happened: the share of oropharyngeal cancer specimens testing HPV-positive climbed from roughly 16 percent in the late 1980s to over 70 percent by the mid-2000s.

The American Cancer Society estimates about 60,480 new oral cavity and oropharyngeal cancer cases in the United States in 2026, with about 13,150 deaths, and attributes the steady rise since the mid-2000s largely to HPV-linked disease.

Who is actually at risk in your operatory

Oral HPV prevalence is not evenly distributed. The CDC reports that about 10 percent of men and 3.6 percent of women carry oral HPV, and that prevalence rises with age. The cancer data skews harder still: of the 18,917 oropharyngeal SCC cases recorded in 2015, 82 percent occurred in men.

This produces a risk profile that does not match the one many practices were trained on. The classic oral cancer patient was a heavy smoker and drinker, typically over 60. The HPV-positive oropharyngeal patient is frequently a man in his 40s, 50s or 60s with limited or no tobacco history, in otherwise good health, with good oral hygiene and no obvious risk markers. Nothing in the intake form flags him.

That is the single most important operational point in this article. A screening protocol that is triggered by tobacco and alcohol history will systematically miss the population now driving the increase.

How HPV-positive disease tends to present

HPV-associated disease favors the base of the tongue and the tonsillar tissue, which places much of it at or beyond the posterior limit of a routine visual oral examination. It also commonly presents with a small primary lesion and a comparatively large cervical lymph node, which means the first noticeable sign is often a persistent neck lump rather than an obvious mucosal change.

Practical implications for the exam:

• Extraoral neck palpation is not optional. For this disease pattern it may be more sensitive than intraoral inspection.
• Ask about unilateral symptoms that have persisted beyond two to three weeks: sore throat, ear pain referred to one side, difficulty swallowing, voice change.
• Retract and inspect the tonsillar pillars and base of tongue deliberately rather than in passing.
• Persistent unilateral findings warrant referral rather than watchful waiting.

Where chairside screening genuinely helps, and where it does not

This deserves to be stated plainly, because it is frequently blurred in marketing material.

There is no approved screening test for oral HPV infection in asymptomatic patients. No adjunctive device detects HPV. Fluorescence visualization devices, including the VELscope, detect changes in tissue fluorescence associated with mucosal abnormality. They do not identify a virus, they do not diagnose, and they do not replace biopsy or referral.

What an adjunctive device does contribute is consistency. It gives the clinician a repeatable structure for examining the accessible mucosa, a documented record of what was examined and when, and a defined process for what happens when something looks wrong. For HPV-driven disease specifically, its value is indirect: it makes the head and neck examination a deliberate, standardized part of every recall rather than something that happens when a patient complains.

The disease that will kill a patient is more likely to be found because a practice examines every patient the same way every time than because any one instrument saw something.

Talking to patients without making it about sex

Clinicians hesitate here, and patients pick up on the hesitation. A few things make the conversation easier:

• Lead with prevalence, not behavior. Oral HPV is common and most exposure clears on its own. That framing is accurate and it lowers the temperature immediately.
• Do not attempt to establish how a patient acquired it. It is not clinically actionable and it damages trust.
• Treat the head and neck exam as routine. Announcing it as a special screening invites the question of why this patient was singled out.
• Point vaccination questions to the physician. CDC recommends HPV vaccination at ages 11 to 12, with catch-up through age 26, and shared clinical decision-making for some adults aged 27 through 45.

What to change on Monday

Three things, in order of impact.

First, decouple your screening trigger from tobacco and alcohol history. The population driving the increase does not carry those risk factors.

Second, add deliberate extraoral neck palpation and a documented posterior oral inspection to every adult recall, not just to patients who present with a complaint.

Third, define in advance what happens when you find something. A persistent unilateral finding at two to three weeks needs a named referral pathway, not a re-evaluation appointment that may or may not get scheduled.

None of this requires new equipment. It requires the exam to be systematic. Practices that want a repeatable structure and a documented record for that exam can review the VELscope Mantis screening device, but the protocol change above is the part that matters most, and it is free.

This article is general clinical information for dental professionals and is not a substitute for diagnosis, individual clinical judgment, or referral. Epidemiological figures are drawn from the CDC and the American Cancer Society.